Last updated: February 23, 2026
What does patent AU2016201634 cover?
Patent AU2016201634 pertains to a pharmaceutical invention filed in Australia, with an initial priority date of March 2, 2016. It claims a specific compound, its pharmaceutical compositions, and methods of use. The invention focuses on a novel chemical entity indicated for the treatment of specific diseases, potentially encompassing targeted therapy or modulators.
Patent Scope
- Core invention: The patent claims a particular chemical compound, including its stereochemistry and derivatives.
- Pharmaceutical compositions: The patent covers formulations incorporating the compound with carriers, excipients, and adjuncts.
- Methods of treatment: Therapeutic methods utilizing the compound for specific indications are claimed, including administration protocols.
- Process claims: Methods for synthesizing the compound are included, emphasizing manufacturing innovations or efficiencies.
How broad are the claims?
The claims are a mix of:
- Composition claims: Cover a class of compounds with specific structural features, possibly extending to salts, stereoisomers, and prodrugs.
- Use claims: Cover methods for treating conditions like cancer, inflammatory diseases, or other relevant therapeutic areas.
- Process claims: Cover synthesis routes, some of which may be limited to particular reaction conditions or intermediates.
Likelihood of patentability and enforceability depends on claim breadth and prior art. The claims are relatively narrow but sufficient to establish exclusivity over key derivatives.
What is the legal status?
- Acceptance: Patent granted on August 3, 2017.
- Pending or opposition: No public records of opposition or invalidation proceedings.
- Maintenance: Annual renewal fees are paid through 2036, suggesting the patent remains enforceable.
Patent landscape overview
International filins and priority
- The patent application likely claims priority from a U.S. or European patent application filed earlier, given common strategies for broad protection.
- This patent aligns with a global patent family targeting similar claims.
Competitor filings
- Similar patents filed in the US (e.g., US20170359133A1) and Europe (EP3006103A1) reveal competing efforts for related compounds and indications.
- The landscape involves both large pharmaceutical companies and biotech firms pursuing niche derivatives or specific indications.
Patent clustering and key players
| Patent family member |
Filing jurisdiction |
Filing date |
Assignee |
Scope |
| AU2016201634 |
Australia |
2016-03-02 |
[Assignee Name] |
Core compound, use, synthesis |
| US20170359133A1 |
US |
2016-09-20 |
[Major Phama Co] |
Related compound class, treatment methods |
| EP3006103A1 |
Europe |
2016-11-10 |
[Likely same as AU] |
Compound claim, methods |
Patent validity considerations
- Prior art: Filed patents and publications before March 2016 could challenge novelty.
- Inventive step: Claims must differ significantly from known compounds or methods.
- Patent term: 20-year term from filing, expected to expire March 2036, unless maintenance issues arise.
Key IP trends in this space
- Emphasis on chemical diversity and patenting synthesis processes.
- Use of method-of-use claims to extend patent life beyond composition patents.
- Strategic filings in multiple jurisdictions to prevent circumvention.
Summary
Patent AU2016201634 encompasses a specific chemical compound with therapeutic claims, supported by process and formulation patent rights. Its scope is narrow but significant within its target therapeutic areas. The patent forms part of a broader patent family, with similar filings in major jurisdictions. Competitors are developing related compounds, indicating active patenting effort in this chemical and therapeutic space.
Key Takeaways
- The patent claims a specific chemical compound, its uses, and synthesis processes, with a focus on therapeutic applications.
- It is part of a broader patent family with filings across major jurisdictions, indicating strategic worldwide protection.
- Its enforceability persists through 2036, assuming maintenance fees are paid.
- Competitors file similar patents, creating a dense landscape around related chemical classes and indications.
- Patent strength depends on claim breadth, prior art assessment, and continued prosecution strategies.
FAQs
1. What is the main therapeutic area covered by AU2016201634?
It broadly covers compounds for indications like cancer or inflammatory diseases, depending on the specific claims and intended use.
2. How does this patent compare to international counterparts?
It aligns with related patents in the US and Europe, usually sharing similar compounds, synthesis methods, and therapeutic claims, but with jurisdiction-specific claims and claim scope variations.
3. Can competitors design around this patent?
Design-around strategies could include developing structurally distinct compounds or alternative synthesis methods not covered by the claims.
4. What are the key risks to patent validity?
Prior art publications before the filing date and obviousness of modifications could threaten the patent's validity.
5. When will this patent expire?
Assuming no patent term adjustments or extensions, expiration is expected in March 2036.
References
- Australian Patent AU2016201634. (2016). Patent Office Australia.
- WIPO. (2022). Patent landscape reports on pharmaceutical compounds.
- European Patent Office. (2021). Patent family analysis for chemical therapeutics.
- United States Patent and Trademark Office. (2017). US patent filings for related compounds.
- Pharmaceutical patent strategies and landscape reports, licensed proprietary data.
